Tech Talk

Private companies and universities are developing new ways to deliver protein drugs.

Industry efforts toward global healthcare surpass average expectations.

Three therapies under review could help Americans attain a healthy weight.

Duke University researchers have found a possible alternative to lyophilization.

Agreement on standards for excipient qualification, development, and fair pricing is underway.

An established show has several new programs that reflect the industry's current challenges.

Contract manufacturers report improving business conditions, but will they continue?

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

Particularly in a more connected world, individual contributions can make a difference.

FDA's Edwin Rivera-Martinez on dodging supply-chain challenges.

A meeting was recently held in Lindau, Germany, to discuss the changing face of pharma and biotech, and how companies can best prepare to face the challenges ahead.

As new process validation guidelines emerge, industry needs to reinvent how it releases product.

Biotech firms must first close the gaps between science and biology on the path toward QbD.

The regulators are doing it. But industry's fear of sharing information may leave them behind.

It can take a lot of work to make sure nothing happens.

Technology can solve enterprise-level problems.

The financial and economic downturn is likey to have long-term implications for outsourcing.

Contract manufacturers of APIs and intermediates report gains, but express caution.

A recent reader poll focused on predictions for the industry's future.

Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.

The past year saw major acquisitions attempted, completed, rejected, and stalled.

Pharmaceutical Technology will feature video coverage of AAPS this month.

Advancements add yet another challenge for industry's already overextended regulatory body.

This year, the employment survey will acknowledge the industry's best employers.

This year's meeting of the Controlled Release Society unveiled a plethora of research insights.

Forums, blogs, and more can spark innovation.

Risk management, and its benefits for patients, plays a big role at the PDA Annual Meeting.

INTERPHEX 2008 offered visitors novel experiences and many stimulating sessions.

The economic case for personalized medicine offers a solution to the industry's recent woes.

Contract manufacturers of APIs and intermediates are cautiously optimistic.